Norditropin(R) Approved For Treatment Of Children With Short Stature Associated With Turner Syndrome

Novo Nordisk announced that Norditropin(R) (somatropin [rDNA origin] injection) received approval from the U.S. Food and Drug Administration (FDA) for the treatment of children with short stature associated with Turner syndrome. Turner syndrome is a rare chromosomal condition caused by complete or partial absence of the second sex chromosome (X chromosome) in females. [click link for full article]

More: continued here

Filed under: Endocrinology on September 25th, 2007